Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

By M. King, S. Wieand, K. Hale, Ming K. Lee, T. Walsh, K. Owens, J. Tait, L. Ford, B. Dunn, J. Costantino and 3 more. Journal of the American Medical Association (JAMA), 2001

781 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics

View Paper: https://www.semanticscholar.org/paper/560fbc5265b6eff7d232fe74a117aecf759df88e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Barbara L. Weber
2. Timothy R. Rebbeck

Citations in the corpus

• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. (2004, background): “Because only eight BRCA1 mutation carriers were diagnosed with breast cancer in the Breast Cancer Prevention Trial [18] (five on tamoxifen and three on placebo) and the results were not statistically significant from that small sample (odds ratio, 1.”